<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02598583</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1210-PNH-103</org_study_id>
    <nct_id>NCT02598583</nct_id>
  </id_info>
  <brief_title>Dose-Escalation Study of ALXN1210 IV in Patients With PNH</brief_title>
  <official_title>An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the safety, tolerability, efficacy, pharmacokinetics,
      pharmacodynamics, and immunogenicity of multiple IV doses of ALXN1210 administered to
      patients with PNH who have not previously been treated with complement inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Lactate Dehydrogenase</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Free Hemoglobin</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Haptoglobin</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Reticulocyte Count</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PNH Red Blood Cell (RBC) Clones</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-dimer</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Manifestations of PNH</measure>
    <time_frame>Baseline to Day 169</time_frame>
    <description>Clinical manifestations are fatigue, abdominal pain, dyspnea, dysphagia, chest pain, and erectile dysfunction. Improvement defined as present at baseline and absent at Day 169. Worsening defined as absent at baseline and present at Day 169.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of ALXN1210 as follows:
Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter
On Day 477, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen as follows:
≥ 40 to &lt;60 kg: 3000 mg every 8 weeks
≥ 60 to &lt;100 kg: 3300 mg every 8 weeks
≥100 kg: 3600 mg every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of ALXN1210 as follows:
Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter
On Day 477, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen as follows:
≥ 40 to &lt;60 kg: 3000 mg every 8 weeks
≥ 60 to &lt;100 kg: 3300 mg every 8 weeks
≥100 kg: 3600 mg every 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALXN1210</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 18 years of age

          2. PNH diagnosis confirmed by documented high-sensitivity flow cytometry

          3. Documented meningococcal vaccination not more than 3 years prior to dosing

          4. Female patients of childbearing potential must use highly effective contraception
             starting at screening and continuing until at least 8 months after the last dose of
             ALXN1210.

          5. Willing and able to give written informed consent and comply with the study visit
             schedule

        Exclusion Criteria:

          1. Treatment with a complement inhibitor at any time

          2. Females who are pregnant, breastfeeding or who have a positive pregnancy test at
             screening or Day 1

          3. Participation in an interventional clinical study within 30 days before initiation of
             dosing on Day 1, or use of any experimental therapy within 30 days prior to dosing on
             Day 1, or within 5 half-lives of the product, whichever is greater

          4. History of allergy to excipients of ALXN1210 or known allergy to Chinese hamster ovary
             (CHO) cell proteins

          5. Inability to comply with study requirements

          6. History of any clinically significant cardiac, hepatic, immunologic, pulmonary, or
             rheumatoid disease that, in the Investigator's judgment, would preclude participation

          7. Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make
             the patient unsuitable for enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Bachman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Ulsan</city>
        <zip>682-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <results_first_submitted>October 30, 2017</results_first_submitted>
  <results_first_submitted_qc>January 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2018</results_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal Nocturnal Hemoglobinuria</keyword>
  <keyword>PNH</keyword>
  <keyword>complement inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ALXN1210 Cohort 1</title>
          <description>Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter</description>
        </group>
        <group group_id="P2">
          <title>ALXN1210 Cohort 2</title>
          <description>Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALXN1210 Cohort 1</title>
          <description>Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter</description>
        </group>
        <group group_id="B2">
          <title>ALXN1210 Cohort 2</title>
          <description>Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="10.87"/>
                    <measurement group_id="B2" value="43.6" spread="13.48"/>
                    <measurement group_id="B3" value="42.4" spread="11.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Lactate Dehydrogenase</title>
        <time_frame>Baseline to Day 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALXN1210 Cohort 1</title>
            <description>Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter</description>
          </group>
          <group group_id="O2">
            <title>ALXN1210 Cohort 2</title>
            <description>Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lactate Dehydrogenase</title>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.952" spread="3.1897"/>
                    <measurement group_id="O2" value="-84.736" spread="3.7736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Free Hemoglobin</title>
        <time_frame>Baseline to Day 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALXN1210 Cohort 1</title>
            <description>Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter</description>
          </group>
          <group group_id="O2">
            <title>ALXN1210 Cohort 2</title>
            <description>Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Free Hemoglobin</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.72" spread="8.343"/>
                    <measurement group_id="O2" value="26.44" spread="10.905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.80" spread="7.948"/>
                    <measurement group_id="O2" value="14.40" spread="6.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.92" spread="12.136"/>
                    <measurement group_id="O2" value="-12.04" spread="9.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Haptoglobin</title>
        <time_frame>Baseline to Day 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALXN1210 Cohort 1</title>
            <description>Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter</description>
          </group>
          <group group_id="O2">
            <title>ALXN1210 Cohort 2</title>
            <description>Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Haptoglobin</title>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.100" spread="0.0000"/>
                    <measurement group_id="O2" value="0.100" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.140" spread="0.0551"/>
                    <measurement group_id="O2" value="0.117" spread="0.0454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.040" spread="0.0551"/>
                    <measurement group_id="O2" value="0.017" spread="0.0454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Reticulocyte Count</title>
        <time_frame>Baseline to Day 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALXN1210 Cohort 1</title>
            <description>Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter</description>
          </group>
          <group group_id="O2">
            <title>ALXN1210 Cohort 2</title>
            <description>Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Reticulocyte Count</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.92" spread="3.354"/>
                    <measurement group_id="O2" value="5.94" spread="2.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="3.014"/>
                    <measurement group_id="O2" value="7.16" spread="4.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="0.757"/>
                    <measurement group_id="O2" value="1.21" spread="4.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PNH Red Blood Cell (RBC) Clones</title>
        <time_frame>Baseline to Day 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALXN1210 Cohort 1</title>
            <description>Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter</description>
          </group>
          <group group_id="O2">
            <title>ALXN1210 Cohort 2</title>
            <description>Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PNH Red Blood Cell (RBC) Clones</title>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.70" spread="15.805"/>
                    <measurement group_id="O2" value="51.46" spread="23.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.05" spread="22.983"/>
                    <measurement group_id="O2" value="60.83" spread="27.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" spread="10.537"/>
                    <measurement group_id="O2" value="9.37" spread="23.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in D-dimer</title>
        <time_frame>Baseline to Day 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALXN1210 Cohort 1</title>
            <description>Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter</description>
          </group>
          <group group_id="O2">
            <title>ALXN1210 Cohort 2</title>
            <description>Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter</description>
          </group>
        </group_list>
        <measure>
          <title>Change in D-dimer</title>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="915.0" spread="1229.00"/>
                    <measurement group_id="O2" value="464.3" spread="290.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608.3" spread="922.57"/>
                    <measurement group_id="O2" value="372.9" spread="164.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-306.7" spread="364.73"/>
                    <measurement group_id="O2" value="-91.4" spread="294.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Manifestations of PNH</title>
        <description>Clinical manifestations are fatigue, abdominal pain, dyspnea, dysphagia, chest pain, and erectile dysfunction. Improvement defined as present at baseline and absent at Day 169. Worsening defined as absent at baseline and present at Day 169.</description>
        <time_frame>Baseline to Day 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALXN1210 Cohort 1</title>
            <description>Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter</description>
          </group>
          <group group_id="O2">
            <title>ALXN1210 Cohort 2</title>
            <description>Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Manifestations of PNH</title>
          <description>Clinical manifestations are fatigue, abdominal pain, dyspnea, dysphagia, chest pain, and erectile dysfunction. Improvement defined as present at baseline and absent at Day 169. Worsening defined as absent at baseline and present at Day 169.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <title>Improved from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change/Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <title>Improved from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change/Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea</title>
              <category_list>
                <category>
                  <title>Improved from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change/Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia</title>
              <category_list>
                <category>
                  <title>Improved from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change/Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain</title>
              <category_list>
                <category>
                  <title>Improved from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change/Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erectile dysfunction</title>
              <category_list>
                <category>
                  <title>Improved from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened from Baseline to Day 169</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change/Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First 169 days of study (through Primary Evaluation date)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ALXN1210 Cohort 1</title>
          <description>Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15
Maintenance phase: 900 mg on Day 29 and each month thereafter</description>
        </group>
        <group group_id="E2">
          <title>ALXN1210 Cohort 2</title>
          <description>Induction phase: 600 mg on Day 1, 900 mg on Day 15
Maintenance phase: 1800 mg on Day 29 and each month thereafter</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Reflux laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric Bachman</name_or_title>
      <organization>Alexion Pharmaceuticals, Inc.</organization>
      <phone>+1.617.613.1057</phone>
      <email>eric.bachman@alexion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

